Skip to Content
Merck
CN
  • Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication.

Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication.

Cancer genetics (2014-12-03)
Eugen C Minca, Raymond R Tubbs, Bryce P Portier, Zhen Wang, Christopher Lanigan, Mary E Aronow, Pierre L Triozzi, Arun Singh, James R Cook, Yogen Saunthararajah, Thomas P Plesec, Lynn Schoenfield, Victoria Cawich, Scott Sulpizio, Roger A Schultz
ABSTRACT

Cytogenetic alterations are strong outcome prognosticators in uveal melanoma (UVM). Monosomy 3 (-3) and MYC amplification at 8q24 are commonly tested by fluorescence in situ hybridization (FISH). Alternatively, microarray analysis provides whole genome data, detecting partial chromosome loss, loss of heterozygosity (LOH), or abnormalities unrepresented by FISH probes. Nonfixed frozen tissue is conventionally used for microarray analysis but may not always be available. We assessed the feasibility of genomic microarray analysis for high resolution interrogation of UVM using formalin-fixed paraffin-embedded tissue (FFPET) as an alternative to frozen tissue (FZT). Enucleations from 44 patients (clinical trial NCT00952939) yielded sufficient DNA from FFPET (n = 34) and/or frozen tissue (n = 41) for comparative genomic hybridization and select single nucleotide polymorphism analysis (CGH/SNP) on Roche-NimbleGen OncoChip arrays. CEP3 FISH analysis was performed on matched cytology ThinPrep material. CGH/SNP analysis was successful in 30 of 34 FFPET and 41 of 41 FZT samples. Of 27 paired FFPET/FZT samples, 26 (96.3%) were concordant for at least four of six major recurrent abnormalities (-3, +8q, -1p, +6p, -6q, -8p), and 25 of 27 (92.6%) were concordant for -3. Results of CGH/SNP were concordant with the CEP3 FISH results in 27 of 30 (90%) FFPET and 38 of 41 (92.6%) FZT cases; partial -3q was detected in two CEP3 FISH-negative cases and whole chromosome 3, 4, and 6 SNP-LOH in one case. CGH detection of -3, +8q, -8p on FFPET and FZT showed significant correlation with the clinical outcome measures (metastasis development, time to progression, survival). Results of the UVM genotyping by CGH/SNP on FFPET are highly concordant with those of the FZT analysis and with those of the CEP3 FISH analysis, and therefore CGH/SNP is a practical method for UVM prognostication. Genome-wide coverage provides additional data with potential relevance to UVM biology, diagnosis, and prognosis.

MATERIALS
Product Number
Brand
Product Description

Supelco
Phenol solution, 5000 μg/mL in methanol, certified reference material
Supelco
Phenol solution, certified reference material, 500 μg/mL in methanol
Sigma-Aldrich
Phenol, Molecular Biology
Sigma-Aldrich
Phenol solution, Saturated with 0.01 M citrate buffer, pH 4.3 ± 0.2, BioReagent, Molecular Biology
Sigma-Aldrich
Phenol, BioXtra, ≥99.5% (GC)
Sigma-Aldrich
Phenol solution, BioReagent, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, Molecular Biology
Sigma-Aldrich
Liquified Phenol, ≥89.0%
Sigma-Aldrich
Phenol, ≥96.0% (calc. on dry substance, T)
Sigma-Aldrich
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC)
Sigma-Aldrich
Phenol, BioUltra, Molecular Biology, ≥99.5% (GC)
Sigma-Aldrich
Phenol, unstabilized, ReagentPlus®, ≥99%
Sigma-Aldrich
Phenol, ≥99%
Sigma-Aldrich
Phenol, ACS reagent, ≥99.0%
Supelco
Phenol solution, 100 μg/mL in acetonitrile, PESTANAL®, analytical standard
Sigma-Aldrich
Phenol, BioUltra, Molecular Biology, TE-saturated, ~73% (T)
Sigma-Aldrich
Phenol, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
Sigma-Aldrich
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, ≥99.5% (GC), crystalline (detached)
Supelco
Phenol, PESTANAL®, analytical standard
Supelco
Phenol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Phenol, unstabilized, purified by redistillation, ≥99%
USP
Phenol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Phenol, natural, 97%, FG